Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine and Inflammation in HIPEC
NCT04106999Phase 3Unknown
- Sponsor
- University of British Columbia
- Start
- Mar 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in inflammation comparing Placebo Arm with Dexmedetomidine Arm (2 arms). Primary endpoint: Inflammatory markers. Status: unknown.
02
Drugs
dexmedetomidine
03
Conditions
inflammation
Beyond the preview
Go deeper on NCT04106999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04106999.